What are your top takeaways in GI Cancers from ASTRO 2024?

Neoadjuvant Chemoradiation (CROSS) vs. Perioperative Chemotherapy (FLOT) in Esophageal Adenocarcinoma (EAC): ESOPEC – a Randomised Controlled Prospective Multicentre Phase III Trial published in issue: October 01, 2024 S6

Has now changed the standard of care for adenoCA of the esophagus. CROSS approach is still valid though for squamous cancers.

1. 168 - Neoadjuvant Toripalimab plus Concurrent Chemoradiotherapy in the Locally Advanced Adenocarcinoma of Esophagogastric Junction: A Phase II Trial - This prospective phase II trial evaluated the efficacy and safety of combining neoadjuvant Toripalimab (a PD-1 inhibitor) with chemoradiotherapy for treating patients with locally advanced adenocarcinoma of the esophagogastric junction (AEG). Forty-three patients received radiotherapy, chemotherapy (capecitabine and oxaliplatin), and immunotherap...

ESOPEC: Dr. Brunner presented the results of a randomized controlled prospective multicenter phase III trial that compared the CROSS vs FLOT regiment among patients with esophageal adenocarcinomas. 438 patients with locally advanced disease (cT1N+ or cT2-4a cN0/+) received their designated therapy prior to esophagectomy. The primary endpoint of 3-year overall survival was higher in the arm that received FLOT compared to CROSS, 57.4% vs 50.7%, respectively. Of note, the group recognizes that one ...